Creo Medical Group - MicroBlate™ Fine commercial update
Creo Medical Group plc
("Creo", the "Company" or the "Group")
MicroBlate™ Fine commercial update
Creo Medical accelerates US clinical adoption and commercial rollout of MicroBlate Fine
First breakthrough case delivering targeted therapy for pancreatic lesions
Creo Medical Group plc (AIM: CREO), the medical device company specialising in advanced energy solutions for therapeutic endoscopy, announces a clinical and commercial update on MicroBlate Fine, its precision microwave ablation platform, as momentum builds across early US clinical adoption and commercial rollout.
MicroBlate Fine has now crossed the threshold of 50 clinical cases worldwide across multiple institutions, with particularly strong engagement from leading US interventional endoscopy centres. MicroBlate Fine is being further evaluated through an international investigator‑led study across the US,
In the US, MicroBlate Fine has recently been used to perform the first endoscopic ultrasound ("EUS") guided microwave ablation of a pancreatic lesion, highlighting its applicability in complex and previously difficult‑to‑treat anatomy. MicroBlate Fine enables EUS‑guided microwave ablation through a flexible 19G needle, providing precise, controlled and homogeneous energy delivery while integrating seamlessly into existing EUS workflows. The device is powered by Creo's CROMA™ Advanced Energy Platform.
Early adoption by US centres of excellence plays a critical role in accelerating broader market acceptance and supports future commercial scale‑up in what represents one of the world's largest therapeutic endoscopy markets. MicroBlate Fine provides a strategic entry point into high‑value microwave ablation procedures, with the potential to enhance recurring revenues and increase utilisation of Creo's broader advanced energy ecosystem, particularly in the US market.
The Company expects continued expansion of site adoption through 2026, alongside growing US clinical engagement, supporting both near‑term revenue generation and longer‑term market penetration in advanced therapeutic endoscopy.
Dr
"As always, patient benefits come first and the fact that previously very sick patients are being put back on to routine follow-up with no evidence of disease at their first follow-up consultation is extremely rewarding for the whole
For further information please contact:
|
Creo Medical Group plc |
||
|
|
Via Walbrook PR |
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser) |
+44 (0)20 7260 1000 |
|
|
|
|
|
|
Shore Capital (Joint Broker) |
+44 (0)20 7408 4090 |
|
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
|
|
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE